Targovax Oy
🇫🇮Finland
- Country
- 🇫🇮Finland
- Ownership
- Subsidiary
- Established
- 2007-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.targovax.com
Clinical Trials
5
Active:1
Completed:2
Trial Phases
2 Phases
Phase 1:4
Phase 2:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials
Phase 1
4 (80.0%)Phase 2
1 (20.0%)A Study of ONCOS-102 in Combination With Other Novel Immune-therapies in Advanced Treatment-resistant Melanoma Patients
Phase 2
Withdrawn
- Conditions
- Melanoma
- First Posted Date
- 2022-09-30
- Last Posted Date
- 2023-06-22
- Lead Sponsor
- Targovax Oy
- Registration Number
- NCT05561491
A Pilot Study of Sequential ONCOS-102, an Engineered Oncolytic Adenovirus Expressing GMCSF, and Pembrolizumab in Patients With Advanced or Unresectable Melanoma Progressing After Programmed Cell Death Protein 1 (PD1) Blockade
Phase 1
Completed
- Conditions
- Advanced or Unresectable Melanoma Progressing After PD1 Blockade
- Interventions
- First Posted Date
- 2016-12-28
- Last Posted Date
- 2021-11-08
- Lead Sponsor
- Targovax Oy
- Target Recruit Count
- 21
- Registration Number
- NCT03003676
- Locations
- 🇺🇸
University of Maryland Comprehensive Cancer Center, Baltimore, Maryland, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
A Randomised Phase II Open-label Study With a Phase Ib Safety lead-in Cohort of ONCOS-102, an Immune-priming GM-CSF Coding Oncolytic Adenovirus, and Pemetrexed/Cisplatin in Patients With Unresectable Malignant Pleural Mesothelioma
Phase 1
- Conditions
- To Determine Safety, Tolerability and Efficacy of ONCOS-102 in Combination With Chemotherapy
- Interventions
- First Posted Date
- 2016-08-26
- Last Posted Date
- 2020-10-08
- Lead Sponsor
- Targovax Oy
- Target Recruit Count
- 31
- Registration Number
- NCT02879669
- Locations
- 🇫🇷
Centre Georges-François Leclerc, Dijon, France
🇫🇷CHU de Rennes - Pontchaillou, Rennes, France
🇪🇸Hospital Universitario Quirón, Barcelona, Spain
ONCOS-102 (Previously CGTG-102) for Therapy of Advanced Cancers
Phase 1
Completed
- Conditions
- Malignant Solid Tumour
- First Posted Date
- 2012-05-15
- Last Posted Date
- 2016-10-24
- Lead Sponsor
- Targovax Oy
- Target Recruit Count
- 12
- Registration Number
- NCT01598129
- Locations
- 🇫🇮
Docrates Hospital, Helsinki, Finland
News
No news found